Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
About this study
This clinical trial evaluates whether having a trained peer navigator helps African American men with prostate cancer that has spread to other parts of the body (metastatic) understand and navigate the genetic testing process better than not having a peer navigator. Genetic testing for men with prostate cancer is very important for making treatment and management decisions. However, understanding the risks, benefits, and steps of genetic counseling and testing can be very challenging for patients. African American men are especially less likely to participant in genetic testing due to lack of awareness or understanding, cultural beliefs, finances, or mistrust of the healthcare system. A peer navigator, someone who helps a patient through the information and the process, may be helpful to some men. This study evaluates whether having a peer navigator throughout the genetic evaluation process helps patients understand and engage in the process more.
- Condition
- Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Tested
- Patient Navigation, Genetic Counseling, Survey Administration, Best Practice, Genetic Counseling, Survey Administration
- Sponsor
- Thomas Jefferson University
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 14
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Provide signed and dated informed consent form
- English speaking only
- Willing to comply with all study procedures and be available for the duration of the study
- Any individual \>= 18 years old
- African American men who meet National Comprehensive Cancer Network (NCCN) criteria for testing will be offered participation.
- These criteria include any one of the following: (1) metastatic prostate cancer (PCA);
- (2) intraductal or ductal pathology;
- (3) T3a or higher;
- (4) grade group 4 or Gleason 8 or higher;
- (5) family history of breast, ovarian, prostate, pancreatic, colorectal, or uterine cancers in 3 or more blood relatives particularly if diagnosed at age \< 50.
- These criteria have been adapted from the NCCN Prostate Cancer (version 2.2021) and NCCN Breast, Ovarian, and Pancreatic (version 2.2021) guideline
Exclusion 2
- Patients that do not meet the inclusion criteria and children under the age of 18 will be excluded
- Anyone who has trouble understanding the consent or with significant anxiety detected during the consent process will also be excluded
Where
1 site, 1 recruiting
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Contact
-
Amy Leader, DrPH, MPH
215-955-7739 Amy.leader@jefferson.edu
Potential match only. Final eligibility is determined by the study team.